200 related articles for article (PubMed ID: 34752846)
21. Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.
Metz EP; Wilder PJ; Dong J; Datta K; Rizzino A
J Cell Physiol; 2020 Apr; 235(4):3731-3740. PubMed ID: 31587305
[TBL] [Abstract][Full Text] [Related]
22. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
Lee HC; Ou CH; Huang YC; Hou PC; Creighton CJ; Lin YS; Hu CY; Lin SC
Oncogene; 2021 Apr; 40(13):2407-2421. PubMed ID: 33664454
[TBL] [Abstract][Full Text] [Related]
23. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Palit SAL; van Dorp J; Vis D; Lieftink C; Linder S; Beijersbergen R; Bergman AM; Zwart W; van der Heijden MS
Sci Rep; 2021 Jul; 11(1):13683. PubMed ID: 34211036
[TBL] [Abstract][Full Text] [Related]
24. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
[TBL] [Abstract][Full Text] [Related]
25. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.
Imoto M; Fujimaki T; Saito S; Tashiro E
J Antibiot (Tokyo); 2021 Oct; 74(10):706-716. PubMed ID: 34282313
[TBL] [Abstract][Full Text] [Related]
27. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
28. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
29. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
30. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
31. Role of Testosterone Levels on the Combinatorial Effect of
Pillai P; Pooleri GK; Nair SV
Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860
[TBL] [Abstract][Full Text] [Related]
32. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
33. Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.
Tsao CW; Li JS; Lin YW; Wu ST; Cha TL; Liu CY
Sci Rep; 2021 Jan; 11(1):1239. PubMed ID: 33441906
[TBL] [Abstract][Full Text] [Related]
34. Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.
Boibessot C; Joncas FH; Park A; Berrehail Z; Pelletier JF; Gris T; Bergeron A; Toren P
Sci Rep; 2021 Sep; 11(1):19299. PubMed ID: 34588590
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
Koivisto CS; Parrish M; Bonala SB; Ngoi S; Torres A; Gallagher J; Sanchez-Hodge R; Zeinner V; Nahhas GJ; Liu B; Cohn DE; Backes FJ; Goodfellow PJ; Chamberlin HM; Leone G
Neoplasia; 2020 Oct; 22(10):484-496. PubMed ID: 32818842
[TBL] [Abstract][Full Text] [Related]
36. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
37. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Farah E; Li C; Cheng L; Kong Y; Lanman NA; Pascuzzi P; Lorenz GR; Zhang Y; Ahmad N; Li L; Ratliff T; Liu X
J Biol Chem; 2019 May; 294(21):8543-8554. PubMed ID: 30940724
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.
Ji G; He S; Huang C; Gong Y; Li X; Zhou L
Int J Biol Sci; 2021; 17(7):1613-1628. PubMed ID: 33994848
[TBL] [Abstract][Full Text] [Related]
40. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]